Cetuximab Clinical Trials
76 recruitingDrug
Phase 142Phase 234Phase 313
Showing 1–20 of 76 trials
Recruiting
Phase 2Phase 3
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Oropharyngeal p16INK4a-Negative Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7+6 more
National Cancer Institute (NCI)613 enrolled339 locationsNCT01810913
Recruiting
Phase 1
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
Stage IV Colorectal Cancer AJCC v8Metastatic Colorectal AdenocarcinomaRecurrent Colorectal Adenocarcinoma+1 more
National Cancer Institute (NCI)30 enrolled15 locationsNCT06102902
Recruiting
Phase 3
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Metastatic Head and Neck Squamous Cell CarcinomaStage IV Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Recurrent Head and Neck Squamous Cell Carcinoma+18 more
National Cancer Institute (NCI)158 enrolled176 locationsNCT06589804
Recruiting
Phase 2
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
Metastatic Skin Squamous Cell CarcinomaLocally Recurrent Skin Squamous Cell Carcinoma
National Cancer Institute (NCI)86 enrolled17 locationsNCT07042295
Recruiting
Phase 1Phase 2
A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)
Lung Neoplasm Malignant
Merck Sharp & Dohme LLC190 enrolled4 locationsNCT07286149
Recruiting
Phase 3
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
AVEO Pharmaceuticals, Inc.410 enrolled112 locationsNCT06064877
Recruiting
Phase 1
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Fate Therapeutics113 enrolled5 locationsNCT07216105
Recruiting
Phase 2
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
Neoplasm Malignant
Merck Sharp & Dohme LLC150 enrolled43 locationsNCT07209111
Recruiting
Phase 3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
Rectal AdenocarcinomaColon Adenocarcinoma
Merck Sharp & Dohme LLC477 enrolled143 locationsNCT06997497
Recruiting
Phase 1Phase 2
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Pancreatic Ductal Adenocarcinoma
Verastem, Inc.295 enrolled13 locationsNCT07020221
Recruiting
Phase 2
A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer
BRAF V600E
Tianjin Medical University Cancer Institute and Hospital49 enrolled4 locationsNCT07506109
Recruiting
Phase 1
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Malignant Neoplasm
Merck Sharp & Dohme LLC250 enrolled14 locationsNCT07247110
Recruiting
Phase 2
Open-label Phase 2 Study of Avutometinib (RAF/MEK Clamp) in Combination With Defactinib (FAK Inhibitor) and Cetuximab in Patients With Unresectable, Anti-EGFR-Refractory Advanced Colorectal Cancer
Advanced Colorectal Cancer
M.D. Anderson Cancer Center33 enrolled1 locationNCT06369259
Recruiting
Phase 1
A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone
Head and Neck Squamous Cell Carcinoma
Boehringer Ingelheim90 enrolled57 locationsNCT06806852
Recruiting
Phase 1
A Study of ASP3082 in Adults With Advanced Solid Tumors
Solid Tumor
Astellas Pharma Inc681 enrolled51 locationsNCT05382559
Recruiting
Phase 2
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Malignant Neoplasm
Merck Sharp & Dohme LLC130 enrolled15 locationsNCT07252739
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Metastatic Colorectal Cancer
Hoffmann-La Roche542 enrolled74 locationsNCT04929223
Recruiting
Phase 1
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Head and Neck CancerHead and Neck Squamous Cell CarcinomaHNSCC+3 more
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT04722523
Recruiting
Phase 1Phase 2
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
University of Chicago53 enrolled1 locationNCT05200442
Recruiting
Phase 1
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)387 enrolled11 locationsNCT06917079